ProMIS Neurosciences. has been granted a patent for antibodies that specifically bind to A-beta oligomers. The patent includes a method for reducing the propagation of these oligomers by administering these antibodies to affected cells or tissues. GlobalData’s report on ProMIS Neurosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on ProMIS Neurosciences, Neuro-degenerative receptor binding drug compositions was a key innovation area identified from patents. ProMIS Neurosciences's grant share as of July 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
Antibodies targeting a-beta oligomers for reducing propagation
The granted patent US12071472B2 outlines methods for addressing amyloid beta (A-beta) oligomer propagation and its associated effects in Alzheimer's disease (AD). Central to these methods is the use of specific antibodies that target A-beta oligomers. The antibodies are characterized by their light and heavy chain variable regions, which include defined complementarity determining regions (CDRs) with specific amino acid sequences (SEQ ID NOs: 74-79). The patent claims methods for reducing A-beta oligomer propagation by administering these antibodies to cells or tissues expressing A-beta oligomers, as well as methods for alleviating symptoms of Alzheimer's disease through similar administration. The patent also details various routes of administration, including parenteral, intravenous, and intranasal, among others.
Additionally, the patent emphasizes the potential for these antibodies to reduce toxicity induced by A-beta oligomers in AD. It includes claims for assessing biological samples for A-beta levels and suggests that the antibodies can be administered alongside other Alzheimer's treatments, such as beta-secretase inhibitors or cholinesterase inhibitors. The methods described may involve direct administration to the central nervous system (CNS) and highlight the importance of monitoring A-beta presence through in vitro measurements or imaging techniques. Overall, the patent presents a comprehensive approach to utilizing specific antibodies in the treatment and management of Alzheimer's disease, focusing on the modulation of A-beta oligomer activity.
To know more about GlobalData’s detailed insights on ProMIS Neurosciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
